Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel

Giorgio Bolis, Giovanna Scarfone, Saverio Tateo, Giorgia Mangili, Antonella Villa, Fabio Parazzini

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. The objective of this open uncontrolled study was to evaluate the toxicity and efficacy of topotecan in ovarian cancer cases with microscopic small residual disease to a first-line treatment, given as sequential treatment, including carboplatinum and paclitaxel. Methods. Inclusion criteria were laparotomically or laparoscopically documented microscopic or macroscopic (50% after first-line treatment. Eligible patients received 1.25 mg/m 2/day of topotecan intravenously as a 30-min infusion for 5 consecutive days every 21 days for four cycles. A total of 38 women entered the study. Surgical "third-look" laparotomy or laparoscopy was performed in patients without clinical/instrumental evidence of progressive disease within 1 month from the last topotecan administration. Results. A complete response was observed in 10 cases (28.6%, 95% confidence interval, based on the Poisson's approximation, 15.6-59.5), a partial response in 1 (2.5 %), progressive disease in 11 (31.4%) and no change/stable disease in 13. The median duration of response was 8 months (range 5-20). The overall 1-year survival after treatment was 82.8% (SE 6.4). Conclusion. This study indicates that sequential therapy with carboplatin plus paclitaxel followed by topotecan, all given at standard doses, is feasible and provides favorable response rates.

Original languageEnglish
Pages (from-to)13-15
Number of pages3
JournalGynecologic Oncology
Volume80
Issue number1
DOIs
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel'. Together they form a unique fingerprint.

Cite this